Economic evaluations of human papillomavirus vaccines

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55, 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur. J. Cancer37(Suppl. 8), S4–S66 (2001).
   PubMed Web of Science ®Google Scholar
• Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J. Natl Cancer Inst.87(11), 796–802 (1995).
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol.189(1), 12–19 (1999).
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine24(Suppl. 3), S11–S25 (2006).
   Web of Science ®Google Scholar
• Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine24(Suppl. 3), S35–S41 (2006).
   Web of Science ®Google Scholar
• Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J. Natl Cancer Inst.91(3), 252–258 (1999).
   PubMedGoogle Scholar
• Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine24(Suppl. 3), S42–S51 (2006).
   Web of Science ®Google Scholar
• Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA287(16), 2114–2119 (2002).
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med.348(6), 518–527 (2003).
   PubMed Web of Science ®Google Scholar
• Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 ASCCP-sponsored Consensus Conference. 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. J. Low. Genit. Tract Dis.6(2), 127–143 (2002).
   PubMedGoogle Scholar
• Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer119(5), 1095–1101 (2006).
   PubMed Web of Science ®Google Scholar
• Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics23(11), 1107–1122 (2005).
   PubMedGoogle Scholar
• Davey E, Barratt A, Irwig L et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet367(9505), 122–132 (2006).
   PubMed Web of Science ®Google Scholar
• Insinga RP, Glass AG, Rush BB. Pap screening in a US health plan. Cancer Epidemiol. Biomarkers Prev.13(3), 355–360 (2004).
   PubMed Web of Science ®Google Scholar
• Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase. Volume 5. IARCPress, Lyon, France (2004).
   Google Scholar
• Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer88(1), 63–73 (2003).
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Harper DM. Chapter 13: current findings from prophylactic HPV vaccine trials. Vaccine24(Suppl. 3), S114–S121 (2006).
   Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med.347(21), 1645–1651 (2002).
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol.6(5), 271–278 (2005).
   PubMed Web of Science ®Google Scholar
• The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.365, 1915–1927 (2007).
   Google Scholar
• Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet364(9447), 1757–1765 (2004).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367(9518), 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer95(11), 1459–1466 (2006).
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol. Rev.28, 88–100 (2006).
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Chapter 18: public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine24(Suppl. 3), S155–S163 (2006).
   Google Scholar
• Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine24(Suppl. 3), S178–S186 (2006).
   Web of Science ®Google Scholar
• Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. The epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med.3(5), E138 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson R, May R. Infectious Diseases of Humans. Dynamics and Control. (1st Edition). Oxford University Press, Oxford, UK (1991).
   Google Scholar
• Garnett GP. An introduction to mathematical models in sexually transmitted disease epidemiology. Sex. Transm. Infect.78(1), 7–12 (2002).
   PubMed Web of Science ®Google Scholar
• Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA290(6), 781–789 (2003).
   PubMed Web of Science ®Google Scholar
• Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis.10(11), 1915–1923 (2004).
   PubMed Web of Science ®Google Scholar
• Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology13(6), 631–639 (2002).
   PubMed Web of Science ®Google Scholar
• Van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am. J. Epidemiol.165(7), 762–775 (2007).
   PubMed Web of Science ®Google Scholar
• French KM, Barnabas RV, Lehtinen M et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br. J. Cancer96(3), 514–518 (2007).
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int. J. Cancer106(6), 896–904 (2003).
   PubMed Web of Science ®Google Scholar
• Kohli M, Ferko N, Martin A et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br. J. Cancer96(1), 143–150 (2007).
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis.13(1), 28–41 (2007).
   PubMed Web of Science ®Google Scholar
• Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J. Natl Cancer Inst. Monogr.(31), 14–19 (2003).
   Google Scholar
• Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL triage study. JAMA285(11), 1500–1505 (2001).
   PubMed Web of Science ®Google Scholar
• Sanders GD, Taira AV. Cost–effectiveness of a potential vaccine for human papillomavirus. Emerg. Infect. Dis.9(1), 37–48 (2003).
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Kohli M, Grima D et al. Projected clinical benefits and cost–effectiveness of a human papillomavirus 16/18 vaccine. J. Natl Cancer Inst.96(8), 604–615 (2004).
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis.13(1), 28–41 (2007).
   PubMed Web of Science ®Google Scholar
• Clifford GM, Smith JS, Aquado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer89(1), 101–105 (2003).
   PubMed Web of Science ®Google Scholar
• Mao C, Koutsky LA, Ault KA et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol.107(1), 18–27 (2006).
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Galvani AP. Vaccination against multiple HPV types. Math. Biosci.197(1), 88–117 (2005).
   PubMed Web of Science ®Google Scholar
• Hughes JP, Garnett GP, Koutsky LA. The theoretical population level impact of a prophylactic human papilloma virus vaccine. Epidemiology13, 631–639 (2002).
   PubMed Web of Science ®Google Scholar
• Kjellberg L, Wang Z, Wiklund F et al. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case–control study. J. Gen. Virol.80(Pt 2), 391–398 (1999).
   PubMed Web of Science ®Google Scholar
• Kataja V, Syrjanen K, Mantyjarvi R et al. Prospective follow-up of cervical HPV infections: life table analysis of histopathological, cytological and colposcopic data. Eur. J. Epidemiol.5(1), 1–7 (1989).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sasieni P. Natural history of cervical human papillomavirus. Lancet358(9292), 1550–1551; discussion 1551–1552 (2001).
   PubMedGoogle Scholar
• Castle PE, Schiffman M, Herrero R et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J. Infect. Dis.191(11), 1808–1816 (2005).
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Bosch FX, Tafur LA et al. Clearance of HPV infection in middle aged men and women after 9 years’ follow up. Sex. Transm. Infect.79(4), 348 (2003).
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Kim JJ, Wright TC. Cost–effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet. Gynecol.103(4), 619–631 (2004).
   PubMed Web of Science ®Google Scholar
• Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer118(1212), 3030–3044 (2006).
   PubMed Web of Science ®Google Scholar
• Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine24(Suppl. 3), S171–S177 (2006).
   PubMedGoogle Scholar
• Institute of Medicine (US) Committee to study priorities for vaccine development. Vaccines for the 21st Century: a Tool for Decision Making. Stratton K, Almario D, McCormick MC (Eds). National Academy Press, WA, USA (2000).
   Google Scholar
• Yuan H, Estes PA, Chen Y et al. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J. Virol.75(17), 7848–7853 (2001).
   PubMed Web of Science ®Google Scholar
• Cost–effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Milton C (Eds). Oxford University Press, NY, USA (1996).
   Google Scholar